Open access
Jul 2026
Effectiveness of Injectable Semaglutide 1 mg/Week in Hepatic Markers, Fibrosis and Systemic Inflammation in Obese Type 2 Diabetes Patients: A 6-Month Retrospective Real-World Study
Background: Type 2 diabetes mellitus is commonly associated with obesity, metabolic liver disease, and chronic low-grade inflammation. Semaglutide is known to improve glycaemic control and body weight, but its real-world associations with hepatic markers, fibrosis-related indices, and systemic inflammatory parameters r...
R. García-Pérez, V. Siles-Guerrero, Aida Elhadri-Egea et al.
· Endocrines · 0 citations